Cel
Globosoft GmbH aims to optimize the drug development process of drug manufacturers, enabling faster and more efficient development of drugs in Europe and worldwide. For this purpose, Globosoft GmbH has developed the innovative optimization algorithm called BioAhead to optimize acid chain analysis, as part of the protein structure modeling field. The innovation will create growth in terms of income and new job creation and have a high return on investment. The proposed model has a high potential for a fast up-take by the market, considering the savings in time and money and also a cloud technology that will make the model easy-to-use in any country. BioAhead adequately addresses issues related to the society. With faster and more accurate drug development processes, the society in Europe and world-wide can benefit from low- priced medicines, faster drug development and highly specialized medicines, which are currently too expensive for economic development.
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesmathematicspure mathematicsmathematical analysis
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural scienceschemical sciencesorganic chemistryamines
- natural sciencescomputer and information sciencessoftwaresoftware applications
Program(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-SMEINST-1-2016-2017
System finansowania
SME-1 - SME instrument phase 1Koordynator
90427 NURNBERG
Niemcy
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.